Margin Peak Holds; Profit Drag Purely Tax—Organic Health Intact

On the headline, profit fell 30% despite revenue up 14.5% and EBITDA surging 35%—a disconnect that management attributes entirely to one-time tax items. The numbers prove the point: EBITDA per TEU ₹2,898 beats the ₹2,400 guidance comfortably, and absolute EBITDA of ₹47 Cr is up 35% year-on-year. The PAT miss is not operational.

The JV dividend tax and prior-year tax adjustments explain the swing. Management expects the tax rate to normalize to 25% going forward, which should restore PAT growth in line with EBITDA. Until that normalization shows in Q2 and Q3 results, reported profit will remain distorted. The operational story—volume +7.2% YoY to 176,499 TEUs, capacity utilization 80–85%, EBITDA margin 22.1%—is sound.

FY30 roadmap quantified: For the first time, management laid out specific FY30 targets—₹1,400 Cr revenue, ₹275 Cr EBITDA (~20% margin), 12.5–13L laden TEUs, 80% utilization. This replaces prior vaguer aspiration of '1M TEU by FY28' with a detailed 3-year trajectory. It's ambitious but grounded in capex (Farukhnagar ICD Q3 '27, Speedy JNPT Jan-Feb '27, Chennai under negotiation).

Dividend pause, capex prioritized: Board declined dividend despite 'high cash-rich business.' Rationale: prioritize ₹400 Cr capex over next 3 years (₹100 Cr in FY27 alone). Funding split: ₹50 Cr accruals, ₹70 Cr annual cash flow, ₹90 Cr raised equity, ₹100–150 Cr debt. Management will revisit dividend post-capex completion; signals growth-over-returns for now.

Management transition: Suresh Kumar (retiring end-August) replaced by Pranav Choudhary (ex-Adani Ports Chief Executive) starting Sept 1. Transition risk: new MD taking charge during capex ramp. Mitigant: Pranav brings port-side logistics expertise; no strategy change announced.

Farukhnagar timeline refined: PFT (port facility terminal) goes live Feb–Mar '27; ICD (inland container depot) follows Q3 FY28. Prior guidance suggested May 2027 for full facility; split timeline aligns with ₹400 Cr capex and de-risks single project concentration.

The stock opened +0.33% on the day of result announcement (delivery 82.3%) but faded to −3.25% by day 3, a clear signal of skepticism post-digestion. At ₹24, it trades above its 20-day SMA (₹23.76) and 50-day SMA (₹23.86), but sits below the 200-day SMA (₹25.5). From a 52-week perspective, it has pulled back 31.6% from the all-time high of ₹35.07 while recovering 31.9% from the low of ₹18.2—a position of equilibrium, not panic or exuberance. FII ownership sits flat at 5.34%; DII trivial at 0.21%; promoter stable at 65.82%. No major insider or bulk flows detected. The flat ownership and below-200-day positioning, combined with the day-3 price fade, reflect the market pricing in genuine concern: (a) PAT −30% despite revenue +14.5% raises earnings quality doubt; (b) margin at 'ideal spot' caps near-term momentum; (c) ₹400 Cr capex is a bet, not a certainty. The market is saying, 'Show us Farukhnagar execution before we chase it higher.'

Watch EBITDA per TEU through the Farukhnagar ramp (Q3 '27 onwards). Current ₹2,898 is peak. If it compresses to ₹2,750 by FY30 as guided, the plan holds. If it compresses faster (to ₹2,600+) or fails to compress (stays at ₹2,750+), it signals either pricing strength (upside surprise) or volume-driven yield pressure (downside risk). This single metric will tell you whether management's 'ideal spot' narrative is defensive positioning or genuine constraint.